⌕
Definium Therapeutics · DFTX · Nasdaq
Tenet 50 · Mixed
Compare
$29.38−2.59%At closeTenet 50 · Mixed
$29.38−0.78 (−2.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Definium Therapeutics (DFTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+226.3%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼69.1%
−183.8
FY21→FY25CAGR —
Diluted EPS▼33.8%
−2.06
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+226.3%

27.4mn → 89.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−117.7R&D−48.6SG&A−166.3Op income−17.5Tax & other−183.8Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6504, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
169,811.0117,665.065,297.052,124.036,169.034,789.0▲80.2%+35.6%
Selling, general & admin
84,343.048,644.038,619.041,742.030,162.059,065.0▲26.0%−4.7%
Total operating expenses
254,154.0166,309.0103,916.093,866.066,331.093,854.0▲60.0%+15.4%
Operating incomefeeds ROC rank
−254,154.0−166,309.0−103,916.0−93,866.0−66,331.0−93,854.0▼60.0%—
Other income, net
−83,327.0−17,484.0−4,763.0−1,866.09,535.0−339.0——
Pretax income
−337,481.0−183,793.0−108,679.0−95,732.0−56,796.0−94,193.0▼69.1%—
Income tax
—————−1,157.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−337,481.0−183,793.0−108,679.0−95,732.0−56,796.0−93,036.0▼69.1%—
Per share
Diluted EPSbuyback-sensitive
−3.04−2.06−1.54−2.44−1.84−3.40▼33.8%—
Diluted shares (mn)
137.3589.3370.4639.1630.8627.38▲26.8%+34.4%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.